¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷) : 2022-04-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷) : 2022-04-01
±³À°ÀÏÀÚ : 2022-04-01
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : Çѹ®¼÷
¿¬¶ôó : 02-566-6031  
À̸ÞÀÏ : icksh@icksh.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 25ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í 100,000¿ø(2¿ù 28ÀÏ ÀÌÀü±îÁö)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-01 Room 1 09:00~09:25 Biologic and clinical consequences of the BRAFV600E mutation in langerhans cell histiocytosis  Kenneth McClain(Texas Children's Cancer Center USA) 
±³À°½Ã°£ 04-01 Room 1 09:25~09:50 Advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis  Kim E. Nichols(St. Jude Children's Research Hospital USA) 
±³À°½Ã°£ 04-01 Room 1 09:50~10:10 Current status of diagnosis and treatment of langerhans cell histiocytosis in Korea  °í°æ³²(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-01 Room 1 10:10~10:30 Adult hemophagocytic lymphohistiocytosis in Korea  ±è¼®Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-01 Room 1 10:30~11:15 Rational development of targeted therapies to cure molecular subtypes of DLBCL(diffuse large B-cell lymphoma)  Louis M. Staudt(National Cancer Institute USA) 
±³À°½Ã°£ 04-01 Room 2 11:30~12:10 The updated information of ponatinib use in chronic myeloid leukemia  Jorge E. Cortes(Georgia Cancer Center USA) 
±³À°½Ã°£ 04-01 Room 2 12:10~12:40 Diabetic Foot Ulcer as a Manifestation of T-Cell Lymphoma: A Case Report  Jumria Tandi Panggalo(Universitas Lambung Indonesia) 
±³À°½Ã°£ 04-01 Room 2 12:40~13:40 Long-term Real-world Experience of Castleman¡¯s Disease Treatment  ¹Î±âÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-01 Room 2 14:40~15:10 Chemotherapy vs. allogeneic HSCT( Hematopoietic Stem Cell Transplantation) for Phnegative adult ALL(acute lymphocytic leukemia)  Josep-Maria Ribera(ICO-Hospital Germans Trias i Pujol Spain) 
±³À°½Ã°£ 04-01 Room 2 15:10~15:40 Clonal heterogeneity in ALL(acute lymphocytic leukemia)  Sophie Park(CHU de Grenoble Service hematologie clinique France) 
±³À°½Ã°£ 04-01 Room 2 15:40~16:10 Challenges in the diagnosis and treatment of overlap MDS(myelodysplastic syndrome)/MPN syndromesmyeloproliferative neoplasm)  Antonio Almeida(Hospital da Luz Lisboa Portugal) 
±³À°½Ã°£ 04-01 Room 4 16:25~16:55 Lymphoma pathology: basic immunohistochemisty for lymphoma diagnosis  Á¶ÁØÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-01 Room 4 16:55~17:25 Staging and response assessment of lymphoma  À¯ÄèÇÑ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-01 Room 4 17:25~17:55 Treatment of indolent lymphoma  Á¤¼ºÇö(ÀÎÇÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷) : 2022-04-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 3) : 2022-04-01
´ÙÀ½±Û (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20775 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 1±â(1ÀÏÂ÷) : 2024-06-13 0 15 2024-05-27
20774 ºÎ»ê (¿Â¶óÀÎ) ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³² ÁöºÎȸ 2024³â 06¿ù Çмú´ëȸ : 2024-06-13 0 10 2024-05-27
20773 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç(1ÀÏÂ÷) : 2024-06-13 0 10 2024-05-27
20772 ´ë±¸ 2024 Á¦2Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ ´ë±¸°æºÏÁöºÎÇÐȸ : 2024-06-13 0 12 2024-05-27
20771 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-13 0 14 2024-05-27
20770 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-13 0 7 2024-05-27
20769 ¼­¿ï 2024³â ±Ýõ±¸ÀÇ»çȸ 1Â÷ ¿¬¼ö±³À°(¿ì¿ïÁõ ¾àÁ¦, ÇǺÎÁúȯ, CBC¿Í LFT, À§¿°) : 2024-06-12 0 3 2024-05-27
20768 ¼­¿ï 2024 Á¦3ȸ ÀÌ°ÇÈñ ¼Ò¾Æ¾Ï¡¤Èñ±ÍÁúȯ ±Øº¹»ç¾÷ ¿¬±¸ÀÚ SKILL-UP Workshop : 2024-06-12 0 6 2024-05-27
20767 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦78Â÷ °æ±âÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-11 0 6 2024-05-27
20766 ±¤ÁÖ Á¦180Â÷ ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2024-06-11 0 8 2024-05-27
20765 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ºÎ»ê,¿ï»ê,°æ³²Áöȸ - Á¦362Â÷ ¿ù·ÊÇмúȸ : 2024-06-11 0 14 2024-05-27
20764 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-11 0 8 2024-05-27
20763 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(ÀÇ»ç) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-06-11 0 21 2024-05-27
20762 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ Á¦ 32ȸ Á¤±â Áý´ãȸ : 2024-06-10 0 16 2024-05-27
20761 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø Á¦16ȸ KOALA Symposium 2024 : 2024-06-09 0 11 2024-05-27
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷